Anacetrapib with statins to lower atherosclerotic heart disease

Atherosclerotic cardiovascular diseases are the largest cause of morbidity and premature death worldwide. REVEAL trial in the European Heart Journal becomes the first randomized controlled trial to demonstrate that adding cholesteryl ester transfer protein inhibitor therapy to intensive statin therapy reduced the risk of major coronary events.

Anacetrapib is used in cholesteryl ester transfer protein (CETP) inhibitor with hypocholesterolemic properties, reportedly used to reduce cholesterol in patients.

The beneficial effects of anacetrapib on major coronary events increased with longer follow-up, and no adverse effects emerged on non-vascular mortality or morbidity. These findings illustrate the importance of sufficiently long treatment and follow-up duration in randomized trials of lipid-modifying agents to assess their full benefits and potential harms.